IMGN News and Press, ImmunoGen Inc. From 05/04/23

2023-05-04 10:31:45 ET Summary ImmunoGen released some outstanding Phase 3 data in relation to its only approved asset ELAHERE yesterday. In its MIRASOL study, ELAHERE met its primary endpoint of Progression Free Survival, as well as the key secondary endpoint of Overall Survival ...

2023-05-04 06:30:00 ET Summary ImmunoGen's Elahere (mirvetuximab soravtansine-gynx) has shown positive results in a confirmatory trial for platinum-resistant ovarian cancer, boosting the company's stock by over 130%. ImmunoGen's Q1 2023 revenues were primarily driven by Elahere sa...

2023-05-03 17:47:21 ET ImmunoGen stock closed up a whopping ~136% on Wednesday after presenting data indicating significant improvement in progression-free and overall survival for ovarian cancer drug Elahere (mirvetuximab soravtansine-gynx). The company said that median PFS in ...

2023-05-03 17:39:48 ET Following another interest rate hike from the Federal Reserve, stocks pushed modestly lower on Wednesday. Amid uncertainty about the future of monetary policy and concerns about the economy, the S&P 500 recorded its third consecutive day of declines. On the ea...

2023-05-03 16:13:15 ET ImmunoGen ( NASDAQ: IMGN ) said Wednesday it intends to offer and sell  $200 million of shares of its common stock in an underwritten public offering. ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additi...

2023-05-03 13:05:45 ET Gainers: ImmunoGen ( IMGN ) +124% . GD Culture Group Limited ( GDC ) +115% . Aptorum Group Limited ( APM ) +92% . Aceragen ( ACGN ) +77% . NantHealth ( NH ) +57% . Sentage Holdings ( SNTG ) +61% ...

2023-05-03 12:10:19 ET ImmunoGen ( NASDAQ: IMGN ) added ~125% on Wednesday to exceed the $2B market cap as Piper Sandler upgraded the stock citing the positive data the biotech announced in the pre-market for its ovarian cancer drug Elahere from a confirmatory Phase 3 trial. ...

2023-05-03 11:53:06 ET Shares of ImmunoGen (NASDAQ: IMGN) were up by 139% Wednesday morning after the company announced positive trial data concerning an ovarian cancer drug the company has in its pipeline. The biotech stock is up more than 151% this year. ImmunoGen specializes ...

2023-05-03 10:01:41 ET Gainers: Aptorum ( APM ) +133% . ImmunoGen ( IMGN ) +123% . Akanda ( AKAN ) +63% . Mersana Therapeutics ( MRSN ) +37% . CNS Pharmaceuticals ( CNSP ) +25% . Losers: Assure ( IONM ) -38% ....

2023-05-03 08:46:05 ET Overall, the stock market is facing a serious case of the jitters on Wednesday morning, as investors wait anxiously for the coming decision on interest rates from the Federal Reserve later this afternoon. Stock index futures are pointing toward a slightly higher open ...